Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual hormones glucagon-like protein-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are amongst the most recent class of incretin-based drugs approved for the treatment of T2D and obesity [8], which is expected to exert potentially beneficial effects on bone health [9]. The gene discussed is GCG; the disease is Obesity.